Sisram Medical Ltd. 1696
HKEX · Hong Kong SAR China · Health Technology
HKD 1.91-0.09 (-4.26%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
International markets outside North America grew 16.7%, while DAXXIFY shipments surpass 30,000 vials in China despite margin pressure.
Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period, the Company achieved steady overall growth, propelled by accelerating momentum in its Injectables business
Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today announced that it will report its unaudited consolidated interim results for the six months ended June 30, 2026 on Wednesday, August 19, 2026.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.